Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: ELISA quantification of CD5L ( A ), CLU ( B ), and SERPINF1 ( C ) protein levels in the vitreous humor of DR and Control patients. * p < 0.05, **** p < 0.0001.

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Enzyme-linked Immunosorbent Assay, Control

Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: Immunohistochemical analysis of CD5L, CLU, and SERPINF1 expression. Immunohistochemical analysis of CD5L, CLU, and SERPINF1 expression in whole-retinal and retinal nerve fiber layer from DR and control SD rats. Images were acquired at 40×magnification, full-field view; scale bar, 25 μm. Nuclei are counterstained blue, and positive staining for CD5L, CLU, and SERPINF1 appears brown. ** p < 0.01, *** p < 0.001.

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Immunohistochemical staining, Expressing, Control, Staining

Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: Prediction of Transcription factors (TFs) and modification sites in key proteins. ( A ) Transcription factor prediction of key proteins. ( B ) Prediction results of PTM sites of key protein APLP2. ( C ) Prediction results of PTM sites of key protein RBP3. ( D ) Prediction results of PTM sites of key protein SERPINF1. ( E ) Prediction results of acetylation of key protein CLU. ( F ) Prediction results of acetylation of key protein PSAP. ( G ) Prediction results of phosphorylation, acetylation, ubiquitination of key protein C5. ( H ) Prediction results of key protein CD5L.

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Modification, Phospho-proteomics, Ubiquitin Proteomics

Journal: Scientific Reports

Article Title: Combined proteomics and metabolomics analyses revealed molecular signatures associated with proliferative diabetic retinopathy

doi: 10.1038/s41598-026-40551-1

Figure Lengend Snippet: Prediction of drug candidates targeting key proteins and functional effects of exogenous CD5L on endothelial cells. ( A ) Molecular docking diagram of key protein RBP3 and drug VITAMIN A PALMITATE. ( B ) Molecular docking diagram of key protein RBP3 and drug VITAMIN A PALMITATE. The purple is the key protein, the iridescent is the drug, and the yellow dotted line is the hydrogen bond between the two, as well as the corresponding bond length and residue. ( C ) EdU assay showing the effect of CD5L on C166 cell proliferation.(Images are shown at 10×magnification, scale bar, 2 μm, proliferating cells are indicated by green fluorescence (EdU), ** p <0.01). ( D ) Scratch wound assay showing the effect of CD5L on C166 cell migration (* p <0.05).

Article Snippet: The C166 + CD5L group was supplemented with 400 pg/mL recombinant CD5L protein (MCE, USA, HY- P72717 ), while the control group received an equal volume of PBS.

Techniques: Functional Assay, Residue, EdU Assay, Fluorescence, Scratch Wound Assay Assay, Migration

Journal: Biochemical and biophysical research communications

Article Title: CD5L is a target of transcription factor Nrf2.

doi: 10.1016/j.bbrc.2025.152225

Figure Lengend Snippet: Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.

Article Snippet: Human rCD5L (2797-CL, R&D Systems) was reconstituted in sterile PBS.

Techniques: Recombinant